Alai Tan
Research Subjects
Alai Tan has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
James S. Goodwin
University of Texas Medical Branch
7 shared publicationsYong-Fang Kuo
University of Texas Medical Branch
5 shared publicationsDaniel H. Freeman
2 shared publicationsJean L. Freeman
Office of Epidemiology and Biostatistics, Department of Preventive Medicine and Community Health, University of Texas Medical Branch, Galveston, TX 77555‐1148, USA
2 shared publicationsHolly M. Holmes
Department of General Internal Medicine, University of Texas MD Anderson Cancer Center, Houston
1 shared publicationJie Zhou
University of Texas Medical Branch
1 shared publication
Latest Publications
- Open Access
- 28 July 2015
- Published by Springer Nature in Journal of General Internal Medicine
- Vol. 31 (2) , 156-163
Variation among Primary Care Physicians in the Use of Imaging for Older Patients with Acute Low Back Pain
Diagnostic imaging is not recommended in the evaluation and management of non-specific acute low back pain.
- 28 July 2015
- Published by Springer Nature in Journal of General Internal Medicine
- Vol. 31 (2) , 156-163
Open AccessVariation among Primary Care Physicians in the Use of Imaging for Older Patients with Acute Low Back Pain
Diagnostic imaging is not recommended in the evaluation and management of non-specific acute low back pain.
- 1 June 2014
- Published by Wolters Kluwer Health in Medical Care
- Vol. 52 (6) , 490-495
Potential Overuse of Screening Mammography and Its Association With Access to Primary Care
Background: Cancer screening in individuals with limited life expectancy increases the risk of diagnosis and treatment of cancer that otherwise would not have become clinically apparent. Objective: To estimate screening mammography use in women with limited life expectancy, its geographic variation, and association with access to primary care and mammographic resources. Methods: We assessed screening mammography use in 2008–2009 in 106,737 women aged 66 years or older with an estimated life expectancy of 1 generalist physician and who had more visits to generalist physicians. There was substantial geographic variation across the United States, with an average rate of 39.5% in the hospital referral regions (HRRs) in the top decile of screening versus 19.5% in the HRRs in the bottom decile. The screening rates were higher among HRRs with more primary care physicians (r=0.14, P=0.02), mammography facilities (r=0.12, P=0.04), and radiologists (r=0.22, P<0.001). Conclusions: Substantial proportions of women with limited life expectancy receive screening mammography. Results presented sound a cautionary note that greater access to primary care and mammographic resources is also associated with higher overuse.
- 1 June 2014
- Published by Wolters Kluwer Health in Medical Care
- Vol. 52 (6) , 490-495
Potential Overuse of Screening Mammography and Its Association With Access to Primary Care
Background: Cancer screening in individuals with limited life expectancy increases the risk of diagnosis and treatment of cancer that otherwise would not have become clinically apparent. Objective: To estimate screening mammography use in women with limited life expectancy, its geographic variation, and association with access to primary care and mammographic resources. Methods: We assessed screening mammography use in 2008–2009 in 106,737 women aged 66 years or older with an estimated life expectancy of 1 generalist physician and who had more visits to generalist physicians. There was substantial geographic variation across the United States, with an average rate of 39.5% in the hospital referral regions (HRRs) in the top decile of screening versus 19.5% in the HRRs in the bottom decile. The screening rates were higher among HRRs with more primary care physicians (r=0.14, P=0.02), mammography facilities (r=0.12, P=0.04), and radiologists (r=0.22, P<0.001). Conclusions: Substantial proportions of women with limited life expectancy receive screening mammography. Results presented sound a cautionary note that greater access to primary care and mammographic resources is also associated with higher overuse.
- Open Access
- 24 May 2014
- Published by Oxford University Press (OUP) in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
- Vol. 70 (2) , 247-254
Coadministration of Co-trimoxazole With Sulfonylureas: Hypoglycemia Events and Pattern of Use
Coadministration of co-trimoxazole with sulfonylureas is reported to increase the risk of hypoglycemia. We identified a cohort of Medicare beneficiaries aged 66 years or older who took glyburide or glipizide for diabetes from a 5% national sample of Medicare Part D claims data in 2008 (n = 34,239). We tracked each participant’s claims during 2008–2010 for a co-trimoxazole prescription and subsequent emergency room visits for hypoglycemia. Descriptive statistics and logistic regression modeling were used to evaluate hypoglycemia-related emergency room visits after coadministration of co-trimoxazole with sulfonylureas and its utilization patterns in older adults with diabetes. Sulfonylureas users prescribed co-trimoxazole had a significant higher risk of emergency room visits for hypoglycemia, compared with those prescribed noninteracting antibiotics (odds ratio = 3.89, 95% confidence interval = 2.29–6.60 for glipizide and odds ratio = 3.78, 95% confidence interval = 1.81–7.90 for glyburide with co-trimoxazole, using amoxicillin as the reference). Co-trimoxazole was prescribed to 16.9% of those taking glyburide or glipizide during 2008–2010, varying from 4.0% to 35.9% across U.S. hospital referral regions. Patients with polypharmacy and with more prescribers were more likely to receive co-trimoxazole. Patients with an identifiable primary care physician had 20% lower odds of receiving a co-trimoxazole prescription. Hospital referral regions with more PCPs had lower rates of coadministration of the two drugs (r = −.26, p < 0.001). Coadministration of co-trimoxazole with sulfonylureas is associated with increased risk of hypoglycemia, compared with noninteracting antibiotics. Such coadministration is prevalent among older diabetic patients in the United States, especially in patients without an identifiable primary care physician.
- 24 May 2014
- Published by Oxford University Press (OUP) in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
- Vol. 70 (2) , 247-254
Open AccessCoadministration of Co-trimoxazole With Sulfonylureas: Hypoglycemia Events and Pattern of Use
Coadministration of co-trimoxazole with sulfonylureas is reported to increase the risk of hypoglycemia. We identified a cohort of Medicare beneficiaries aged 66 years or older who took glyburide or glipizide for diabetes from a 5% national sample of Medicare Part D claims data in 2008 (n = 34,239). We tracked each participant’s claims during 2008–2010 for a co-trimoxazole prescription and subsequent emergency room visits for hypoglycemia. Descriptive statistics and logistic regression modeling were used to evaluate hypoglycemia-related emergency room visits after coadministration of co-trimoxazole with sulfonylureas and its utilization patterns in older adults with diabetes. Sulfonylureas users prescribed co-trimoxazole had a significant higher risk of emergency room visits for hypoglycemia, compared with those prescribed noninteracting antibiotics (odds ratio = 3.89, 95% confidence interval = 2.29–6.60 for glipizide and odds ratio = 3.78, 95% confidence interval = 1.81–7.90 for glyburide with co-trimoxazole, using amoxicillin as the reference). Co-trimoxazole was prescribed to 16.9% of those taking glyburide or glipizide during 2008–2010, varying from 4.0% to 35.9% across U.S. hospital referral regions. Patients with polypharmacy and with more prescribers were more likely to receive co-trimoxazole. Patients with an identifiable primary care physician had 20% lower odds of receiving a co-trimoxazole prescription. Hospital referral regions with more PCPs had lower rates of coadministration of the two drugs (r = −.26, p < 0.001). Coadministration of co-trimoxazole with sulfonylureas is associated with increased risk of hypoglycemia, compared with noninteracting antibiotics. Such coadministration is prevalent among older diabetic patients in the United States, especially in patients without an identifiable primary care physician.
- Open Access
- 12 July 2013
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 178 (6) , 974-983
Predicting Life Expectancy for Community-dwelling Older Adults From Medicare Claims Data
Estimates of life expectancy are useful in assessing whether different prevention strategies are appropriate in different populations. We developed sex-specific Cox proportional-hazard models that use Medicare claims data to predict life expectancy and risk of death at up to 10 years for older adults. We identified a cohort of Medicare beneficiaries 66–90 years of age from the 5% Medicare claims data in 2000 (n = 1,137,311) and tracked each subject's vital status until December 31, 2009. Subjects were split randomly into training and validation samples. Models were developed from the training sample and validated by comparison of predicted to actual survival in the validation sample. The C statistics for the models including predictors of age and Elixhauser comorbidities were 0.76–0.79 for men and women for prediction of death at the 1-, 5-, 7-, and 10-year follow-up periods. More than 80% of subjects with <25% risk of death at 5, 7, and 10 years survived longer than the chosen cutoff years. More than 80% of subjects with ≥75% risk of death at 5, 7, and 10 years died by those cutoff years. The models overestimated the risk of death at 1 year for the high-risk groups. Sex-specific models that use age and Elixhauser comorbidities can accurately predict patient life expectancy and risk of death at 5–10 years.
- 12 July 2013
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 178 (6) , 974-983
Open AccessPredicting Life Expectancy for Community-dwelling Older Adults From Medicare Claims Data
Estimates of life expectancy are useful in assessing whether different prevention strategies are appropriate in different populations. We developed sex-specific Cox proportional-hazard models that use Medicare claims data to predict life expectancy and risk of death at up to 10 years for older adults. We identified a cohort of Medicare beneficiaries 66–90 years of age from the 5% Medicare claims data in 2000 (n = 1,137,311) and tracked each subject's vital status until December 31, 2009. Subjects were split randomly into training and validation samples. Models were developed from the training sample and validated by comparison of predicted to actual survival in the validation sample. The C statistics for the models including predictors of age and Elixhauser comorbidities were 0.76–0.79 for men and women for prediction of death at the 1-, 5-, 7-, and 10-year follow-up periods. More than 80% of subjects with <25% risk of death at 5, 7, and 10 years survived longer than the chosen cutoff years. More than 80% of subjects with ≥75% risk of death at 5, 7, and 10 years died by those cutoff years. The models overestimated the risk of death at 1 year for the high-risk groups. Sex-specific models that use age and Elixhauser comorbidities can accurately predict patient life expectancy and risk of death at 5–10 years.
- 3 July 2013
- Published by Taylor & Francis in Breast Cancer Management
- Vol. 2 (4) , 263-265
Screening mammography in older women: the balance between appropriate use and overuse
- 3 July 2013
- Published by Taylor & Francis in Breast Cancer Management
- Vol. 2 (4) , 263-265
Screening mammography in older women: the balance between appropriate use and overuse
- 1 March 2013
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 61 (3) , 380-387
Refining Physician Quality Indicators for Screening Mammography in Older Women: Distinguishing Appropriate Use from Overuse
Objectives: To assess the feasibility of refining physician quality indicators of screening mammography use based on patient life expectancy. Design: Retrospective population‐based cohort study. Setting: Texas. Participants: Three thousand five hundred ninety‐five usual care providers ( UCP s) with at least 10 female patients aged 67 and older on January 1, 2008, with an estimated life expectancy of 7 years or more (222,584 women) and at least 10 women with an estimated life expectancy of less than 7 years (90,903 women), based on age and comorbidity. Measurements: Screening mammography use in 2008–09 by each provider in each population. Results: The average adjusted mammography screening rates for UCP s were 31.1% for women with a life expectancy of less than 7 years and 55.2% for women with a life expectancy of 7 years or longer. For women with limited life expectancy, 3.7% of UCP s had significantly lower and 9.2% had significantly higher than average adjusted mammography screening rates. For women with longer life expectancy, 16.7% of UCP s had significantly lower and 19.7% had significantly higher than average rates. UCP adjusted screening rates were stable over time (2006–07 vs 2008–09, correlation coefficient ( r ) = 0.65, P < .001). There was a strong correlation between UCP screening rates for their female patients with a life expectancy of less than 7 years and 7 years or longer ( r = 0.67, P < .001). Most physician characteristics associated with higher screening rates (e.g., being female and foreign trained) in women with longer life expectancy were also associated with higher screening rates in women with limited life expectancy. Conclusion: Providers with high mammography screening rates for women with longer life expectancy also tend to screen women with limited life expectancy. Quality indicators for screening practice can be improved by distinguishing appropriate use from overuse based on patient life expectancy.
- 1 March 2013
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 61 (3) , 380-387
Refining Physician Quality Indicators for Screening Mammography in Older Women: Distinguishing Appropriate Use from Overuse
Objectives: To assess the feasibility of refining physician quality indicators of screening mammography use based on patient life expectancy. Design: Retrospective population‐based cohort study. Setting: Texas. Participants: Three thousand five hundred ninety‐five usual care providers ( UCP s) with at least 10 female patients aged 67 and older on January 1, 2008, with an estimated life expectancy of 7 years or more (222,584 women) and at least 10 women with an estimated life expectancy of less than 7 years (90,903 women), based on age and comorbidity. Measurements: Screening mammography use in 2008–09 by each provider in each population. Results: The average adjusted mammography screening rates for UCP s were 31.1% for women with a life expectancy of less than 7 years and 55.2% for women with a life expectancy of 7 years or longer. For women with limited life expectancy, 3.7% of UCP s had significantly lower and 9.2% had significantly higher than average adjusted mammography screening rates. For women with longer life expectancy, 16.7% of UCP s had significantly lower and 19.7% had significantly higher than average rates. UCP adjusted screening rates were stable over time (2006–07 vs 2008–09, correlation coefficient ( r ) = 0.65, P < .001). There was a strong correlation between UCP screening rates for their female patients with a life expectancy of less than 7 years and 7 years or longer ( r = 0.67, P < .001). Most physician characteristics associated with higher screening rates (e.g., being female and foreign trained) in women with longer life expectancy were also associated with higher screening rates in women with limited life expectancy. Conclusion: Providers with high mammography screening rates for women with longer life expectancy also tend to screen women with limited life expectancy. Quality indicators for screening practice can be improved by distinguishing appropriate use from overuse based on patient life expectancy.
- 1 March 2012
- Published by Elsevier in American Journal of Preventive Medicine
- Vol. 42 (3) , 229-234
Integrating Age and Comorbidity to Assess Screening Mammography Utilization
- 1 March 2012
- Published by Elsevier in American Journal of Preventive Medicine
- Vol. 42 (3) , 229-234
Integrating Age and Comorbidity to Assess Screening Mammography Utilization
- 9 October 2007
- Published by Wiley in Biometrical Journal
- Vol. 49 (5) , 707-718
Evaluating Health Care Performance: Strengths and Limitations of Multilevel Analysis
An increasing number of health services researchers are using multilevel analysis for evaluating health care performance. This method has the distinct advantage of accounting for within‐provider correlation among patients. Alternatively, in a similar manner, estimators based on cluster sampling can also adjust for within‐provider correlation. Cluster sampling methods do not require assumptions about error distribution as multilevel analysis does. To our knowledge, no comparison has been made between multilevel analysis and cluster sampling estimators in evaluating health care performance using either a simulated or real dataset. In this paper, we compare the cluster sampling estimators to multilevel estimators in evaluating screening mammography performance using Medicare claims data. We also discuss the strengths and limitations of multilevel analysis in profiling health care providers with small caseloads.
- 9 October 2007
- Published by Wiley in Biometrical Journal
- Vol. 49 (5) , 707-718
Evaluating Health Care Performance: Strengths and Limitations of Multilevel Analysis
An increasing number of health services researchers are using multilevel analysis for evaluating health care performance. This method has the distinct advantage of accounting for within‐provider correlation among patients. Alternatively, in a similar manner, estimators based on cluster sampling can also adjust for within‐provider correlation. Cluster sampling methods do not require assumptions about error distribution as multilevel analysis does. To our knowledge, no comparison has been made between multilevel analysis and cluster sampling estimators in evaluating health care performance using either a simulated or real dataset. In this paper, we compare the cluster sampling estimators to multilevel estimators in evaluating screening mammography performance using Medicare claims data. We also discuss the strengths and limitations of multilevel analysis in profiling health care providers with small caseloads.
- 4 July 2006
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 100 (3) , 309-318
Variation in false-positive rates of mammography reading among 1067 radiologists: a population-based assessment
The accuracy of mammography reading varies among radiologists. We conducted a population-based assessment on radiologist variation in false- positive rates of screening mammography and its associated radiologist characteristics.
- 4 July 2006
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 100 (3) , 309-318
Variation in false-positive rates of mammography reading among 1067 radiologists: a population-based assessment
The accuracy of mammography reading varies among radiologists. We conducted a population-based assessment on radiologist variation in false- positive rates of screening mammography and its associated radiologist characteristics.